Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- AVXL
- Price
- 8.86
- Stock movement up
- +0.32 (3.75%)
- Company name
- Anavex Life Sciences Corp
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 751.29M
- Ent value
- 624.29M
- Price/Sales
- -
- Price/Book
- 5.79
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 8.78%
- 1 year return
- 106.53%
- 3 year return
- -10.36%
- 5 year return
- 25.46%
- 10 year return
- 22.98%
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
AVXL does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 5.79 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 84.80M |
| EPS (TTM) | -0.49 |
| FCF per share (TTM) | -0.35 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -48.44M |
| Net income (TTM) | -41.53M |
| EPS (TTM) | -0.49 |
| EPS (1y forward) | -0.68 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 138.76M |
| Net receivables | 1.72M |
| Total current assets | 141.53M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 141.53M |
| Accounts payable | 3.50M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 11.75M |
| Total liabilities | 11.75M |
| Shareholder's equity | 129.78M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -30.00M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -30.00M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -32.00% |
| Return on Assets | -29.34% |
| Return on Invested Capital | -32.23% |
| Cash Return on Invested Capital | -23.28% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 8.63 |
| Daily high | 8.98 |
| Daily low | 8.41 |
| Daily Volume | 700K |
| All-time high | 28.86 |
| 1y analyst estimate | 35.47 |
| Beta | 0.60 |
| EPS (TTM) | -0.49 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 7 May 2025 |
Downside potential
Loading...
Downside potential data
| AVXL | S&P500 | |
| Current price drop from All-time high | -69.30% | -12.89% |
| Highest price drop | -97.06% | -56.47% |
| Date of highest drop | 19 Nov 2014 | 9 Mar 2009 |
| Avg drop from high | -66.13% | -11.07% |
| Avg time to new high | 41 days | 12 days |
| Max time to new high | 3301 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
751.29M
Marketcap category
Small-cap
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Employees
40
Website
Investor relations
-
SEC filings
CEO
Christopher U. Missling
Country
USA
City
New York
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page